FDA Approves Beyfortus™ (Nirsevimab-Alip) to Protect Infants against RSV Disease

The US FDA has approved Sanofi and AstraZeneca’s Beyfortus™ for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants born during or entering their first RSV season.